Prognosis
BioNTech Sees Potential to Supply 3 Billion Doses in 2022
- CEO Sahin says lifting vaccine production depends on demand
- Company already in discussion about Covid booster shots
This article is for subscribers only.
Sign up here for our daily coronavirus newsletter on what you need to know, and subscribe to our Covid-19 podcast for the latest news and analysis.
BioNTech SE could have capacity to make 3 billion doses of Covid-19 vaccine with U.S. partner Pfizer Inc. next year, the German company’s chief executive officer said, making their pioneering shot far more widely available around the world.